Compare Alibaba Group (BABA) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Illumina, Inc. — how do they compare? Alibaba Group trades at $116.9 (market cap $270.95B), while Illumina, Inc. trades at $191.2 (market cap $28.93B). The key difference: Alibaba Group is far larger — about 9.4× Illumina, Inc.'s market cap, and Alibaba Group pays a 0.93% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| BABA | ILMN | |
|---|---|---|
Market Cap | $270.95B | $28.93B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $194.33 |
52-Week Low | $94.83 | $91.00 |
Enterprise Value | $265.77B | $30.32B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $112.35, up 0.02% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with robust fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 17.36 appear reasonable. The stock faces headwinds from securities investigations but benefits from AI-driven optimism in cloud growth.
Outlook remains positive given Wall Street's $195 price target and 86% buy ratings, though risks include legal overhangs and earnings volatility. AI and cloud initiatives offer growth catalysts, but investors should monitor regulatory developments and quarterly execution against expectations.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
